Lessons From Adaptive Randomization: Spying the I-SPY2 Trial in Breast Cancer

Jardim DL, Schwaederle M, Hong DS, . An appraisal of drug development timelines in the era of precision oncology. Oncotarget 2016;7:53037–53046.

• Crossref
• PubMed
Jardim DL, Schwaederle M, Hong DS, . An appraisal of drug development timelines in the era of precision oncology. Oncotarget 2016;7:53037–53046.2741963210.18632/oncotarget.10588)| false
• Search Google Scholar
• Export Citation

Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med 2017;177:1569–1575.

• Crossref
Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med 2017;177:1569–1575.10.1001/jamainternmed.2017.3601)| false
• Search Google Scholar
• Export Citation

Dowden H, Munro J. Trends in clinical success rates and therapeutic focus. Nat Rev Drug Discov 2019;18:495–496.

• Crossref
• PubMed
Dowden H, Munro J. Trends in clinical success rates and therapeutic focus. Nat Rev Drug Discov 2019;18:495–496.3126706710.1038/d41573-019-00074-z)| false
• Search Google Scholar
• Export Citation

Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016;375:65–74.

• Crossref
• PubMed
Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016;375:65–74.10.1056/NEJMra151006127406349)| false
• Search Google Scholar
• Export Citation

Harrington D, Parmigiani G. I-SPY 2—a glimpse of the future of phase 2 drug development? N Engl J Med 2016;375:7–9.

• Crossref
• PubMed
Harrington D, Parmigiani G. I-SPY 2—a glimpse of the future of phase 2 drug development? N Engl J Med 2016;375:7–9.10.1056/NEJMp160225627406345)| false
• Search Google Scholar
• Export Citation

Park JW, Liu MC, Yee D, . Adaptive randomization of neratinib in early breast cancer. N Engl J Med 2016;375:11–22.

• Crossref
• PubMed
Park JW, Liu MC, Yee D, . Adaptive randomization of neratinib in early breast cancer. N Engl J Med 2016;375:11–22.10.1056/NEJMoa151375027406346)| false
• Search Google Scholar
• Export Citation

Rugo HS, Olopade OI, DeMichele A, . Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med 2016;375:23–34.

• Crossref
• PubMed
Rugo HS, Olopade OI, DeMichele A, . Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med 2016;375:23–34.10.1056/NEJMoa151374927406347)| false
• Search Google Scholar
• Export Citation

Chien AJ, Tripathy D, Albain KS, . MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2-positive and/or hormone receptor-negative breast cancers in the I-SPY 2 trial. J Clin Oncol 2020;38:1059–1069.

• Crossref
• PubMed
Chien AJ, Tripathy D, Albain KS, . MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2-positive and/or hormone receptor-negative breast cancers in the I-SPY 2 trial. J Clin Oncol 2020;38:1059–1069.3203188910.1200/JCO.19.01027)| false
• Search Google Scholar
• Export Citation

DeMichele AM, Moulder S, Buxton M, . Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: results from the neoadjuvant I-SPY 2 trial. Presented at the AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, Louisiana.

• Crossref
DeMichele AM, Moulder S, Buxton M, . Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: results from the neoadjuvant I-SPY 2 trial. Presented at the AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, Louisiana.10.1158/1538-7445.AM2016-CT042)| false
• Export Citation

Nanda R, Liu MC, Yau C, . Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol 2020;6:676.

• Crossref
• PubMed
Nanda R, Liu MC, Yau C, . Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol 2020;6:676.3205313710.1001/jamaoncol.2019.6650)| false
• Search Google Scholar
• Export Citation

Pusztai L, Han HS, Yau C, . Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: results from the I-SPY 2 trial. Presented at the AACR Annual Meeting; April 27, 2020; virtual.

Loibl S, O’Shaughnessy J, Untch M, . Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 2018;19:497–509.

• Crossref
• PubMed
Loibl S, O’Shaughnessy J, Untch M, . Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 2018;19:497–509.2950136310.1016/S1470-2045(18)30111-6)| false
• Search Google Scholar
• Export Citation

Cortazar P, Geyer CE Jr. Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol 2015;22:1441–1446.

• Crossref
• PubMed
Cortazar P, Geyer CE Jr. Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol 2015;22:1441–1446.10.1245/s10434-015-4404-825727556)| false
• Search Google Scholar
• Export Citation

Cortazar P, Zhang L, Untch M, . Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384:164–172.

• Crossref
• PubMed
Cortazar P, Zhang L, Untch M, . Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384:164–172.2452956010.1016/S0140-6736(13)62422-8)| false
• Search Google Scholar
• Export Citation

Gyawali B, Hey SP, Kesselheim AS. Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs [published online April 22, 2020]. EClinicalMedicine, doi: https://doi.org/10.1016/j.eclinm.2020.100332journal

Gyawali B, Hey SP, Kesselheim AS. Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs [published online April 22, 2020]. EClinicalMedicine, doi: https://doi.org/10.1016/j.eclinm.2020.100332journal)| false
• Search Google Scholar
• Export Citation

Gianni L, Pienkowski T, Im YH, . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25–32.

• Crossref
• PubMed
Gianni L, Pienkowski T, Im YH, . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25–32.2215389010.1016/S1470-2045(11)70336-9)| false
• Search Google Scholar
• Export Citation

Baselga J, Bradbury I, Eidtmann H, . Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633–640.

• Crossref
• PubMed
Baselga J, Bradbury I, Eidtmann H, . Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633–640.10.1016/S0140-6736(11)61847-322257673)| false
• Search Google Scholar
• Export Citation

von Minckwitz G, Procter M, de Azambuja E, . Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017;377:122–131.

• Crossref
von Minckwitz G, Procter M, de Azambuja E, . Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017;377:122–131.10.1056/NEJMoa1703643)| false
• Search Google Scholar
• Export Citation

Piccart-Gebhart M, Holmes E, Baselga J, . Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol 2016;34:1034–1042.

• Crossref
• PubMed
Piccart-Gebhart M, Holmes E, Baselga J, . Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol 2016;34:1034–1042.2659874410.1200/JCO.2015.62.1797)| false
• Search Google Scholar
• Export Citation

Niraula S, Amir E, Vera-Badillo F, . Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. J Clin Oncol 2014;32:3634–3642.

• Crossref
• PubMed
Niraula S, Amir E, Vera-Badillo F, . Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. J Clin Oncol 2014;32:3634–3642.2526775710.1200/JCO.2014.55.8437)| false
• Search Google Scholar
• Export Citation

Delaloge S, Cella D, Ye Y, . Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. Ann Oncol 2019;30:567–574.

• Crossref
• PubMed
Delaloge S, Cella D, Ye Y, . Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. Ann Oncol 2019;30:567–574.3068970310.1093/annonc/mdz016)| false
• Search Google Scholar
• Export Citation